VOLUME 23 NUMBER 10 OCTOBER 2016 nature structural & molecular biology a r t i c l e s HIV-1 Env, the only target of neutralizing antibodies, is among the most heavily glycosylated proteins ever characterized 1 . It includes glycans, constituting up to 50% of its mass, attached to 30 ± 3 potential N-linked glycosylation sites (PNGSs) per gp120-gp41 protomer. Viral glycans are generally nonimmunogenic because they are assembled by host-cell machinery; thus, carbohydrates decorating the surface of Env constitute a 'glycan shield' that reduces access to underlying protein epitopes 2 . Structural studies of bNAbs bound to Env trimers have revealed mechanisms by which bNAbs targeting various epitopes penetrate the glycan shield to either accommodate or include N-glycans in their epitopes [3] [4] [5] [6] [7] [8] [9] . The structure of the HIV-1 Env glycan shield itself, however, remains incompletely characterized.
a r t i c l e s HIV-1 Env, the only target of neutralizing antibodies, is among the most heavily glycosylated proteins ever characterized 1 . It includes glycans, constituting up to 50% of its mass, attached to 30 ± 3 potential N-linked glycosylation sites (PNGSs) per gp120-gp41 protomer. Viral glycans are generally nonimmunogenic because they are assembled by host-cell machinery; thus, carbohydrates decorating the surface of Env constitute a 'glycan shield' that reduces access to underlying protein epitopes 2 . Structural studies of bNAbs bound to Env trimers have revealed mechanisms by which bNAbs targeting various epitopes penetrate the glycan shield to either accommodate or include N-glycans in their epitopes [3] [4] [5] [6] [7] [8] [9] . The structure of the HIV-1 Env glycan shield itself, however, remains incompletely characterized.
Because of steric constraints that limit the activities of endoplasmic reticulum and Golgi carbohydrate-processing enzymes, the HIV-1 Env glycoprotein includes regions of underprocessed N-glycans in oligomannose forms (Man [5] [6] [7] [8] [9] GlcNAc 2 ), particularly in the intrinsic mannose patch on gp120, which forms portions of the epitopes for many characterized HIV-1 bNAbs 10 . Although oligomannose glycans dominate parts of HIV-1 Env, such as the N332 gp120 glycan-associated region on gp120, processed complex-type N-glycans predominate at N-linked glycosylation sites on gp41 and gp41-proximal regions of gp120 (ref. 11) and are thought to protect the host receptor (CD4)-binding site (CD4bs) and the V3 loop of gp120 (ref. 12) .
Because all Env crystal structures to date have been solved by using glycoproteins produced in exclusively high-mannose forms 2-6,9,13-20 , little is known about the structure of the native HIV-1 Env glycan shield that includes both complex-type and oligomannose N-glycans. A 4.2-Å cryo-EM structure of a natively glycosylated Env trimer reveals some ordered complex-type N-glycans near the gp120-gp41 interface, but much of the remaining Env glycan content is not visible 8 . Thus, the natively glycosylated epitopes of important HIV-1 bNAb classes, such as N332 gp120 glycan/V3 loop and CD4bs bNAbs, remain incompletely characterized. Here we set out to define the complete epitopes of two HIV-1 bNAbs, which recognize the gp120 V3 loop and CD4bs, respectively, in the context of a natively glycosylated Env trimer.
The accessibility to the conserved CD4bs on gp120 is restricted by surrounding glycans that have, to date, been visualized in structural studies involving Env proteins including only high-mannose N-glycans 9, 13, 14, [18] [19] [20] . However, vaccine-design efforts to elicit CD4-mimetic bNAbs [21] [22] [23] [24] [25] [26] [27] have been aided by crystal structures revealing that VRC01-class bNAbs mimic CD4 binding and thus share a common mode of gp120 binding and glycan accommodation by using a VH1-2*02-derived variable heavy (V H ) domain 14, [18] [19] [20] 28 . Although VRC01-class bNAbs are attractive candidates for immunogen design, their features, such as a high degree of somatic hypermutation (SHM) and a short (five-residue) light chain (LC) complementarity-determining region 3 (CDRL3) (found in only 1% of human LCs 29 ) suggest that they might be difficult to elicit through vaccination. Here we describe IOMA, a new class of CD4-mimetic bNAb derived from the VH1-2*02 germline, which has a normal-length CDRL3 and includes fewer SHMs than do VRC01-class bNAbs. We defined IOMA's complete epitope, and the epitope of the V3-loop-directed bNAb 10-1074 (ref. 30) , by using crystal structures of a fully and natively glycosylated Env trimer. Analysis of the native glycan shield on HIV-1 Env allowed us to provide what is, to our knowledge, the first full description of the interplay between heterogeneous untrimmed high-mannose and complex-type N-glycans within the CD4bs and V3-loop epitopes on Env, thereby revealing antibody-vulnerable glycan holes and roles of complex-type N-glycans on Env that are relevant to vaccine design.
RESULTS

Isolation and characterization of IOMA
IOMA, a new VH1-2-derived CD4bs bNAb ( Fig. 1 and Supplementary  Figs. 1-3) , was isolated by single-cell B-cell cloning 31 from an HIV-1-infected ART-treated patient. IOMA accounts for most of the neutralizing activity in this patient's serum, as demonstrated by a comparison of neutralization activities of serum IgG and purified IOMA (Fig. 1b) . Unlike other CD4bs bNAbs, IOMA has relatively few SHMs (22 HC and 15 LC amino acid changes from the germline, as compared with 41 and 25 changes for VRC01), yet IOMA neutralized ~50% of tested strains with a mean half-maximal inhibitory concentration (IC 50 ) of 2.3 µg/mL (Supplementary Fig. 2 ) and a breadth and potency superior to those of CD4bs bNAbs with similar SHM rates (for example, b12) but inferior to those of CD4bs bNAbs with increased SHMs 32, 33 (Fig. 1c) . IOMA is an interesting target for structural studies because it combines features of VH1-2/VRC01-class bNAbs with a second related but distinct set of CD4-mimetic CD4bs bNAbs derived from the VH1-46 germline gene segment 19 . Like VH1-46, but unlike VH1-2 bNAbs, IOMA includes a normal-length (eight residue) CDRL3 (Supplementary Note and Supplementary Fig. 3 ).
Structures of natively glycosylated Env-bNAb complexes
Crystallization trials were conducted with complexes of the native-like Env trimer BG505 SOSIP.664 (ref. 34 ) and bNAb Fabs. Previous trimer crystal structures have included Env produced in cells that attached only high-mannose-type N-glycans [3] [4] [5] [6] 9 , which, with two exceptions 5, 9 , were enzymatically trimmed to reduce glycans to single N-acetylglucosamines (GlcNAcs) at accessible PNGSs. Our crystals, obtained from natively glycosylated BG505 SOSIP.664 prepared from human cells that attached both complex-type and high-mannose N-glycans, were complexed with Fabs from IOMA and 10-1074, a V3 loop/N332 gp120 glycan-directed bNAb in the PGT121-124 family 30 . We solved independent structures of the IOMA-10-1074-BG505 complex by using BG505 protein prepared from different sizeexclusion chromatography (SEC) fractions ( Supplementary Fig. 4 Table 1) . The IOMA-10-1074-BG505 structures revealed an Env trimer bound to three 10-1074 and three IOMA Fabs (Fig. 1d) . 19 N-glycans (one GlcNAc up to complex-type tetra-antennary) were visible per gp120-gp41 protomer, forming arrays of glycans extending ~30 Å from the trimer surface ( Fig. 2a-c) . We observed apparent N-glycan differences in the Env portions of the 3.5-Å-and 3.9-Å-resolution structures ( Fig. 2a and Supplementary Figs. 5-8 ).
Glycan interpretation and refinement
We interpreted glycans in the 3.9-Å and 3.5-Å IOMA-10-1074-BG505 structures by using 2F o − F c maps calculated with model phases and using composite annealed omit maps calculated with phases in which the model was omitted to reduce model bias 35 . Although glycan heterogeneity complicated modeling, we were often able to assign glycans at individual PNGSs as complex type or high mannose (Supplementary Figs. 5-8) . The 3.9-Å structure sometimes showed more density for individual BG505 N-glycans than the 3.5-Å structure (Supplementary Figs. 5-8) , a result consistent with the apparently greater degree of glycosylation suggested by the SEC and SDS-PAGE characteristics of the BG505 protein in crystals used for the lowerresolution structure (Supplementary Fig. 4 ). We assigned glycans as complex type if there was density for a core fucose and/or on the basis of mass spectroscopy assignments 11, 36 . A core fucose was sometimes visible in one structure but not the other. We therefore interpreted glycans at some individual PNGSs as having different compositions in the two structures (Supplementary Figs. 5-8) ; such heterogeneity is consistent with the multiple glycoforms at single PNGSs identified in preparations of BG505 SOSIP.664 protein 11 .
In general, the composite annealed omit electron density maps showed more density near PNGSs than the maps calculated with model phases (Fig. 2a and Supplementary Figs. 5-8) ; some of the extra density was not interpretable, and therefore we did not build glycan residues into these regions. In addition, some glycans were only partially ordered. Thus, a complex-type glycan could appear in our electron density maps to be a small high-mannose glycan if the core fucose and residues beyond mannose rings were disordered. In addition, the assignment of a glycan as complex type or high mannose was also not always clear because the core pentasaccharide portion of an N-glycan is common to both high-mannose and complex-type N-glycans. In other cases, our glycan interpretation was partially based on experimental data: for example, for the N301 gp120 glycan, a core fucose was not ordered in our electron density maps, but we modeled the N301 gp120 glycan as complex type in our structures, on the basis of mass spectrometry data 36 .
Although we built and refined glycan structures by using PDB CArbohydrate REsidue check (pdbcare) (http://www.glycosciences. de/tools/pdb-care/), CArbohydrate Ramachandran Plot (carp) (http:// www.glycosciences.de/tools/carp/), and Privateer 37 , coordinates for glycans in our structures should be regarded as approximate (especially for regions outside the core pentasaccharide common to both complex-type and high-mannose N-glycans). The glycan density was sometimes ambiguous, as was expected given the large degree of glycan heterogeneity in HIV-1 Env, one of the most heavily glycosylated proteins known 10 . However, in agreement with the assumption that uninterpretable glycan density resulted from heterogeneity in the sample rather than from problems in refinement, we found unambiguous density at positions assumed to be homogenous, such as N332 gp120 , a high-mannose-only site 11 , whereas sites predicted to be more heterogeneous, such as N276 gp120 (refs. 11,36) (interpreted as complex type in our structures), exhibited some unassigned and uninterpretable heterogeneous electron density ( Supplementary Figs. 5-8 ).
Although the relatively low resolution of our crystal structures and heterogeneous glycosylation compounded inherent difficulties in making unambiguous glycan assignments, we built coordinates into very extensive densities (for example, glycan attached to N156 gp120 ), even if the exact structure of the glycan was uncertain, in order to allow the overall extent of glycosylation at each site to be appreciated. Additional confidence in electron density interpretation came from comparing the independently refined 3.9-Å and 3.5-Å IOMA-10-1074-BG505 structures ( Table 1) . Despite caveats regarding the N-glycan coordinates, the crystal structures revealed a relatively highresolution view of a native glycan-shield structure that could be used for assessments of the roles of complex-type N-glycans in antibody recognition and HIV-1 Env function.
By comparison with the 4.2-Å cryo-EM structure of a natively/ fully glycosylated Env 8 , we observed a more extensively glycosylated trimer, particularly adjacent to the V3 loop and CD4bs, and the apex and gp120-gp41-interface regions of the BG505 trimer in our structures showed clusters of complex-type N-glycans not observed in fully (but not natively) glycosylated Env crystal structures 9 (Fig. 2b) . We generated electron density maps at individual PNGSs and compared glycan assignments for ordered BG505 SOSIP.664 N-glycans in the 3.9-Å and 3.5-Å IOMA-10-1074-BG505 structures with glycans at analogous PNGSs in the fully and natively glycosylated 4.2-Å EM structure of a native (i.e., non-SOSIP) version of the JR-FL Env trimer 8 ; the fully but not natively glycosylated 3.7-Å crystal structure of BG505 SOSIP.664 (i.e., high-mannose-only glycans that were not Regions of gp120 and gp41 that are not surface accessible are shown in wheat and pink, respectively. Binding sites for IOMA (blue) and 10-1074 (green) are highlighted. Second and fourth panels, glycans displayed on the BG505 surface, with sequence conservation among 116 HIV-1 strains colorcoded from white (low sequence identity) to purple (high sequence identity). Arrow points to N241 gp120 (yellow sphere in first panel), a PNGS in 97% of HIV-1 strains but not in BG505. The dotted ovals in the first two panels indicate an N241 gp120 -adjacent region of low sequence conservation that also lacks glycan density (same region shown on two adjacent protomers in each panel), which may represent an antibody-vulnerable glycan hole that would be targeted by strain-specific antibodies. npg a r t i c l e s enzymatically trimmed 9 , a structure chosen for comparison instead of the 3. Figs. 5-8 ). Although the BG505 SOSIP.664 construct 34 was used both for our structures and for the mass spectrometry analysis 11 , some differences in glycans at individual PNGSs between the mass spectrometry study and our structures might be expected if the crystals preferentially incorporated a subset of the glycosylation states within the BG505 protein.
10-1074 interactions with natively glycosylated Env trimer
Although N332 gp120 glycan-targeting bNAbs can adopt different Env-binding orientations 3, 38 , the 10-1074 orientation resembled those of PGT121-124 family bNAbs, and, as seen in structures of BG505 bound to other PGT121-related bNAbs 3, 6, 39 , the N332 gp120 glycan was packed into a groove formed by 10-1074's CDRH3, CDRL1, and CDRL2 ( Fig. 3a-c) . In addition to the N332 gp120 glycan (Man 8 GlcNAc 2 in our 3.5-Å and 3.9-Å structures), PGT121 family bNAbs 6 are surrounded by glycans attached to N156 gp120 (modeled as complex-type tetra-antennary at 3.9-Å resolution; Supplementary  Fig. 5 ), N301 gp120 (modeled as complex-type biantennary at 3.9-Å resolution; Supplementary Fig. 7 ), and N137 gp120 (disordered); thus, our structures provide what is, to our knowledge, the first visualization of the V3 loop/N332 gp120 glycan-dependent epitope in the context of complex-type N-glycosylation. The presence of complex-type N-glycans potentially carrying negatively charged terminal sialic acids in the vicinity of the 10-1074 epitope on Env trimers may account for the increased electropositivity of the 10-1074 combining site during affinity maturation 40 .
In agreement with studies demonstrating that 10-1074-lineage bNAbs are more sensitive to removal of the N332 gp120 glycan than PGT121-lineage bNAbs in neutralization assays 30 , the primary interaction for 10-1074 was with the N332 gp120 glycan (1,440 Å 2 total buried surface area (BSA)), and there were secondary or minimal interactions with the N301 gp120 (209 Å 2 BSA) and N156 gp120 (<40 Å 2 BSA) glycans, respectively (Fig. 3c-f and Table 2) , and contacts as previously described with the 'GDIR' peptide motif in the gp120 V3 loop 3, 6, 39 (Fig. 3g) . Rotation of the LC's third-framework region (FWRL3) in bound versus unbound 10-1074 (ref. 30 ) probably illustrates accommodation of the N301 gp120 glycan (Fig. 3d,f) . Analysis of the 10-1074 interaction interface rationalizes fine specificity differences with other PGT121-family members: in PGT122, compared with 10-1074, rotation of PGT122's CDRL3 combined with an S95R LC substitution may enhance its interaction with the N156 gp120 glycan (Fig. 3e) . Indeed, PGT122 was approximately two-fold more potent against strains including the N156 gp120 PNGS, whereas 10-1074 showed approximately four-fold-greater potency against viral strains lacking the N156 gp120 PNGS (Supplementary Fig. 9a,b) .
IOMA interactions with natively glycosylated Env trimer
Although the Env binding orientation of IOMA differed somewhat from the orientations of both VH1-2/VRC01-class and VH1-46/8ANC131-class bNAbs (Supplementary Fig. 10a) , the IOMA-BG505 interaction (Fig. 4) shared CD4-mimetic features of both VH1-2/VRC01-class and VH1-46/8ANC131-class bNAbs, including the R71 HC -D368 gp120 interaction and CDRH2 mimicking the C″ strand of CD4 (refs. 18,19) (Supplementary Fig. 10b,c) .
VH1-2/VRC01-class bNAbs are distinguished from VH1-46/ 8ANC131-like bNAbs by their five-residue CDRL3s, W50 HC (VH1-2 germline encoded), and CDRH3-encoded residue W100B HC 29 . IOMA contains W50 HC and W47 HC , but, in contrast to VH1-2/VRC01-class bNAbs, these residues do not contact gp120 (Figs. 4b and 5a) . IOMA also includes a counterpart of the signature CDRH3 W100B HC residue in VRC01-class bNAbs. In VH1-2/VRC01-class bNAbs, this tryptophan (Kabat numbering 100B; usually located four residues before the CDRH3 C terminus) is the most conserved antigen-facing residue within CDRH3, and its side chain indole nitrogen hydrogen-bonds with a side chain oxygen of N279 gp120 (Fig. 4b) . The IOMA HC includes a tryptophan five residues from the C-terminal end of CDRH3 (Kabat numbering 100F) (Supplementary Note and Supplementary Fig. 3a ). IOMA's W100F HC preserved the interactions observed for VRC01-class W100B HC with N279 gp120 /N280 gp120 (Fig. 4b) .
8ANC131-like bNAbs use their normal-length CDRL3s in place of a W100B HC residue to interact with N279 gp120 /N280 gp120 (Figs. 4b and 5b) . IOMA is unique in having both an N279 gp120 /N280 gp120 -W'100B HC ' interaction and a normal-length CDRL3, a combination made possible because its CDRL3 is displaced from gp120 loop D and toward the V5 loop (Fig. 5b) . We further addressed the question of how IOMA recognizes Env with a normal-length CDRL3 together with signature VRC01-class residues by comparing Env interactions with IOMA, VH1-2/VRC01-class, and VH1-46/8ANC131-class bNAbs. In 8ANC131-class bNAbs, the longer CDRL3 interacts with N279 gp120 / D279 gp120 (Fig. 4b) , and the C-terminal portion of CDRH3 is farther from loop D (Fig. 5b) . In VRC01-class bNAbs, E96 LC (within a fiveresidue CDRL3) hydrogen-bonds with N280 gp120 (Fig. 4c) and makes a backbone contact to G459 gp120 (Fig. 5c) . IOMA's eight-residue CDRL3 also includes a negatively charged residue, D93 HC , that interacts with R456 gp120 and N280 gp120 (Figs. 4c and 5c) . However, IOMA's longer CDRL3 is accommodated by a shift in BG505's gp120 V5 loop, relative to its position in gp120s complexed with VH1-2/VRC01-class bNAbs, . Orientation for PGT124 was generated by modeling the gp120 of a PGT124-gp120 structure (PDB 4R2G) onto BG505. (c-e) Structural overlays of 10-1074 and other PGT121 family members in regions near the glycans attached to N332 gp120 (c), N301 gp120 (d), and N156 gp120 (e). 10-1074 apo is the structure of the unbound Fab (PDB 4FQ2). (f) Observed and potential interactions with N301 gp120 glycan. F67 LC in the LC of the BG505-bound 10-1074 Fab is shifted from its position in the unbound 10-1074 Fab structure (10-1074 apo; PDB 4FQ2) to accommodate the N301 gp120 glycan. The red starburst in the model of 10-1074 apo aligned with 10-1074 from the IOMA-10-1074-BG505 structure indicates a predicted clash. F67 LC from the LCs of the PGT121 INT and PGT122 Fabs in complex structures with BG505 could accommodate the N301 gp120 glycan if the glycan were oriented as in the IOMA-10-1074-BG505 structure, but a clash (red starburst) is predicted between F67 LC from the LC of PGT124 and the N301 gp120 glycan unless the glycan is shifted from this position. (g) Interactions with GDIR motif. Similarly to other PGT121-124 family bNAbs 3,6,39 , 10-1074 reaches through the glycan shield and contacts the GDIR peptide motif (G324 gp120 -D325 gp120 -I326 gp120 -R327 gp120 ) in the gp120 V3 loop. PGT121 INT (Figs. 4c and 5d ). IOMA's D93 LC -R456 gp120 interaction is not found in VRC01-class bNAbs, wherein N58 HC interacts with the backbone of R456 gp120 . In IOMA, the VH1-2 germline residue N58 HC is mutated to K58 HC , which interacts with the backbone of N280 gp120 , a similar interaction to that in 8ANC131 (Fig. 4c) . The hydrophobic gp120 pocket, which normally accommodates F43 CD4 (ref. 2 ) and has been targeted by engineered substitutions of G54 HC in VRC01-class bNAbs 14 , is filled by R54 HC (Fig. 4d) , as seen in a gp120-complex structure with 1B2530, a VH1-46-derived bNAb 19 . 
r t i c l e s
The IOMA Fab is framed on both sides by Env N197 gp120 and N276 gp120 glycans, interpreted as complex-type biantennary and tetra-antennary, respectively, in the 3.9-Å structure, with minor interactions with a high-mannose glycan at N363 gp120 ( Supplementary Fig. 10d and Table 2 ). IOMA accommodates the N276 gp120 glycan with a short α-helix in CDRL1 instead of the extended loop in other CD4-mimetic bNAbs (Fig. 6a-d) . The need for CDRL1 to accommodate the glycan attached to N276 gp120 is a barrier to the development of VRC01-class bNAbs 19, 20 that is typically overcome by CDRL1 deletions or by SHM introducing multiple glycine residues 20 (Fig. 6e) . The VL2-23-derived CDRL1 of IOMA has no indels and is two or three residues longer than the CDRL1 of the common VRC01-class LCs KV1-33 and KV3-20, and IOMA's CDRL1 acquired only one additional glycine residue during SHM (G29 LC ). The short α-helix in IOMA's CDRL1 is a CDRL1 conformation not observed in available structures of VRC01-class or 8ANC131-class bNAbs (Fig. 6a-d) . However, this helical conformation (designated L1-14-02 in refs. 41, 42) is common in the CDRL1s of antibodies derived from human germline VL2-23 and the closely related VL2-14 and VL2-8 germlines. For example, gp41-targeting bNAbs 3BC176 and 3BC315, which share germline VH and VL genes with IOMA, have CDRL1 loops in the same helical conformation as npg a r t i c l e s in IOMA (PDB 5AWN and 5CCK) 43 . VL2-14-derived bNAbs PG9, PG16, and 35O22 (PDB 3U4E, 4DQO, and 4TVP) 4,44,45 also include α-helical CDRL1s. Although VRC01-class bNAb VRC-PG20 derives from VL2-14, its CDRL1 has a six-residue deletion and does not have a helical conformation 20 .
In contrast with observed interactions in structures of VH1-2/VRC01-class bNAb-Env complexes 13, 14, [18] [19] [20] , IOMA interacts extensively with the Env N276 gp120 and N197 gp120 glycans. Of the 1,839 Å 2 BSA, 749 Å 2 involved these glycans ( Table 2) , which are either not present in gp120 constructs used for crystallization (N197 gp120 ) or disordered (N276 gp120 ) in most VRC01-class-gp120 structures. To compare how IOMA and other VH1-2-derived bNAbs accommodate these glycans, we evaluated the neutralization potencies of IOMA and VRC01-class bNAbs against HIV-1 YU2 pseudoviruses with N197 gp120 or N276 gp120 glycan deletions (Supplementary Fig. 9c,d) . The results suggested that glycosylation at N197 gp120 (98% conserved) is accommodated better by IOMA than by the VRC01-class bNAbs VRC01 or NIH45-46, with both IOMA and the VRC01-class bNAbs showing a slight preference for removal of the N276 gp120 glycan (95% conserved). IOMA's similar ability to that of VRC01 for accommodating the N276 gp120 glycan, one of the primary roadblocks in the development of VRC01-class bNAbs 20, 32 , required relatively small changes from its germline CDRL1 sequence (Fig. 6e) . This aspect may favor the development of IOMA-like bNAbs and relate to IOMA's distinct Env-binding orientation ( Supplementary  Fig. 10a ) and α-helical CDRL1 (Fig. 6a) .
DISCUSSION
Gaps in the glycan shield
The 10-1074 and IOMA footprints are apparent as contiguous solvent-accessible surface areas when mapped onto the natively glycosylated BG505 structure (Fig. 2c, green and blue) . The footprints fall in Env regions that are relatively conserved in sequence (Fig. 2c, dark purple) , thus rationalizing why both antibodies are broadly neutralizing. These results are consistent with those from a recent study reporting that neutralizing antibodies target glycan-deficient patches; i.e., holes in the glycan shield 46 . Potential antibody epitopes that elicit strain-specific, but not broadly neutralizing, antibodies should be apparent as holes in the glycan shield (Fig. 2c, red) in which the exposed surface exhibits low sequence conservation (Fig. 2c, white or light purple) . A glycan-deficient region adjacent to N241 gp120 (a PNGS in 97% of HIV-1 strains, but not BG505) (Fig. 2c, dotted oval) also shows low sequence conservation, thus suggesting that this region represents a hole in the glycan shield that could be targeted by autologous but not broadly neutralizing antibodies.
Implications for vaccine design to elicit CD4bs bNAbs VH1-2/VRC01-class bNAbs are promising targets for vaccine design because they evolved in multiple donors and recognize HIV-1 Env through conserved interactions 14, [18] [19] [20] 28, 29, 33 . The IOMA-BG505 structure demonstrating that VH1-2-derived CD4-mimetic bNAbs Left, interface between gp120 (gray) and IOMA (HC, dark blue; LC, light blue), demonstrating interactions between IOMA D93 LC and gp120 residues R456 gp120 , G459 gp120 , and N280 gp120 . Right, interface between gp120 (gray) and VRC01 (HC, dark green; LC, light green) demonstrating interactions between VRC01 E96 LC and residues G459 gp120 and N280 gp120 . (d) V5-loop shift. To accommodate IOMA's normal-length CDRL3, there is a shift in BG505's V5 loop in the IOMA-10-1074-BG505 structure compared with V5 loops in complex structures of gp120s bound to VRC01 and 8ANC131.
a r t i c l e s are not limited to five-residue CDRL3s suggests an additional pathway for vaccine elicitation by immunogens targeting VRC01-class bNAbs. To elicit VRC01-class bNAbs, immunogens have been designed to bind to inferred VH1-2 germline precursors [21] [22] [23] [24] [25] . In transgenic mice expressing germline VRC01-class HCs, the designed immunogens select VH1-2 B-cells with short CDRL3s 22, 27 , although relatively few clones with five-residue CDRL3s have been isolated, thus reflecting their low frequency (~1% of LCs) 29 . The existence of bNAbs that combine features of VRC01-like and 8ANC131-like classes has implications for immunization strategies targeting VRC01-like bNAbs. First, VRC01-class-targeting immunogens may also initially elicit IOMA-like antibodies; thus, studies using these immunogens should examine whether IOMA-like antibodies (i.e., VH1-2 Abs with longer CDRL3s) are also elicited. Indeed, isolation of naive B cells binding to the VRC01-class germline-targeting immunogen eOD-GT8 was found to enrich VH1-2-expressing cells from 4% to 50%, but 70% of eOD-GT8-binding/VH1-2-expressing cells do not express an antibody with a five-residue CDRL3 (ref. 25); some or even most of these may represent B cells with IOMA-like antibody receptors.
In the context of eliciting CD4-mimetic bNAbs, IOMA represents an alternative pathway from VRC01-class bNAbs. Although this pathway may not lead to bNAbs with the breadth and potency of VRC01-like bNAbs, it is possible that the IOMA pathway may more readily lead to an effective vaccine response, owing to higher frequencies of normal-length CDRL3s compared with the rare five-residue CDRL3s required for VRC01-class bNAbs 29 , and a lower need for SHM. The isolation of fewer IOMA-like bNAbs than VRC01-class bNAbs to date may have resulted from only the most broadly neutralizing sera having been investigated. Regardless of whether elicitation of IOMA-like antibodies is desirable for VH1-2-targeting immunogens, knowledge of this binding mode opens the possibility of immunogen design to either favor or disfavor this pathway.
METHODS
Methods and any associated references are available in the online version of the paper. LC of VRC01 from a VRC01-gp120 structure (PDB 3NGB). The N276 gp120 glycan was disordered in this structure. (c) LC of 8ANC131 from an 8ANC131-gp120 structure (PDB 4RWY). The N276 gp120 glycan was disordered in this structure. (d) LC from 45-46m2 (an engineered VRC01-class bNAb 13 ) from a 45-46m2-gp120 structure (PDB 4JKP). The N276 gp120 glycan was partially ordered in this structure. Glycans are shown as sticks; color-coded as shown in key. (e) Changes in CDRL1 versus germline for CD4-mimetic bNAbs. The mechanism by which each CDRL1 accommodates the N276 gp120 glycan is highlighted in yellow. The reduced breadth and potency of DRVIA7 compared with other VRC01-class bNAbs appears to be due to its LC 32 .
a r t i c l e s complex type in our structures (Supplementary Fig. 5 ) but has been identified as high mannose (primarily Man 9 GlcNAc 2 ) in mass spectrometry analyses of BG505 SOSIP.664 (ref. 11). When we modeled a high-mannose glycan at this site and carried out refinement as described above, we found a slight increase (0.1%) in R free and electron density in addition to that accounted for by the highmannose residues, including density for a core fucose. We also modeled the N-linked glycan attached to N392 gp120 as containing a core fucose ( Supplementary  Fig. 8 ), but it has been identified as a Man 9 GlcNAc 2 /Man 8 GlcNAc 2 mixture in BG505 SOSIP.664 mass spectroscopy studies 11 . When the core fucose was removed from the N392 gp120 glycan coordinates, a subsequent refinement showed a minor increase in R free , and electron density for the fucose was preserved. Buried surface areas were determined with PDBePISA 57 and a 1.4-Å probe. Superimposition calculations were performed, and molecular representations were generated with PyMOL (http://www.pymol.org/) or UCSF Chimera 58 . PDBeFold 59 was used to perform pairwise Cα alignments. The following distance and geometry criteria were used for assigning putative hydrogen bonds: a distance of <3.5 Å and an A-D-H angle of >90°. The maximum distance allowed for a van der Waals interaction of 4.0 Å. Hydrogen-bond and van der Waals interaction assignments should be considered tentative, owing to the relatively low resolutions of the structures.
Antibody approach-angle comparisons. The angles of approach for selected CD4bs bNAbs were compared as follows: the structure of CD4 in complex with HxBc2 gp120 (PDB 1GC1) was used as a reference structure for comparisons of angles of approach of Fab recognition of gp120s. The center of mass of the CD4 D1 domain was placed at the origin, and its principal axes of inertia were aligned with the Cartesian axes with AMORE from the CCP4 suite 54 . The remainder of the PDB 1GC1 complex was then aligned with the centered CD4 D1 domain. To compare with other complexes, each Fab-gp120 complex was aligned with the 1GC1 gp120 chain with LSQMAN 60 . The transformation matrix between the aligned Fab-gp120 V H domain and the CD4 D1 domain was then calculated by LSQMAN.
Antibody dendrogram calculation. CD4-mimetic bNAb V H -gene-segment nucleotide sequences were aligned with Clustal Omega 61 , and the resulting multiple sequence alignment was input into PhyML 62 to calculate a phylogenic tree with tree topology and branch-length optimization (the tree improvement setting was 'best of NNI and SPR'). Dendrograms were drawn with FigTree (http://tree.bio.ed.ac.uk/software/figtree/).
